Latest Tobacco cessation Stories
An Extensive UCSF Study Questions Previous Study’s Analytic Methods San Francisco, CA (PRWEB) May 05, 2012 A popular smoking cessation medication has
A popular smoking cessation medication has been under a cloud of suspicion ever since the Canadian Medical Association Journal (CMAJ) published a study in July 2011 reporting "risk of serious adverse cardiovascular events associated with varenicline."
A major research trial to test the effectiveness of extra support for smokers calling an NHS quitline - on top of what is already offered by the service - has found the additional help does not improve success rates for quitting the habit.
Aside from the obvious health issues, smoking can be an expensive habit and yet millions of smokers continue to set light to thousands of dollars a year to support this addiction.
A nicotinic drug approved for smoking cessation significantly improved the walking ability of patients suffering from an inherited form of ataxia, reports a new clinical study led by University of South Florida researchers.
Good news for those who are trying to quit smoking and drinking, there may be a way to kill two birds with one stone. Varenicline, an effective smoking-cessation medication, may also reduce drinking. However, the means by which it might reduce drinking are still unclear.